Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D.

Science. 2018 Oct 12;362(6411). pii: eaar3593. doi: 10.1126/science.aar3593.

PMID:
30309915
2.

Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial.

Bays HE, Patel MD, Mavros P, Ramey DR, Tomassini JE, Tershakovec AM, Baxter CA.

J Clin Lipidol. 2017 Jul - Aug;11(4):929-937. doi: 10.1016/j.jacl.2017.04.121. Epub 2017 May 8.

PMID:
28647412
3.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T.

Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761.

4.

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.

Toth PP, Catapano AL, Farnier M, Foody J, Tomassini JE, Jensen E, Polis AB, Hanson ME, Musliner TA, Tershakovec AM.

Am J Cardiol. 2016 Dec 15;118(12):1812-1820. doi: 10.1016/j.amjcard.2016.08.071. Epub 2016 Sep 13.

5.

Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice.

Catapano AL, Lautsch D, Tokgözoglu L, Ferrieres J, Horack M, Farnier M, Toth PP, Brudi P, Tomassini JE, Ambegaonkar B, Gitt AK.

Atherosclerosis. 2016 Sep;252:1-8. doi: 10.1016/j.atherosclerosis.2016.07.007. Epub 2016 Jul 14.

6.

Statin combination therapy and cardiovascular risk reduction.

Toth PP, Farnier M, Tomassini JE, Foody JM, Tershakovec AM.

Future Cardiol. 2016 May;12(3):289-315. doi: 10.2217/fca-2015-0011. Epub 2016 Apr 15. Review.

PMID:
27079178
7.

Time-related trends in variability of cIMT changes in statin trials.

Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM.

Data Brief. 2015 Dec 30;6:530-41. doi: 10.1016/j.dib.2015.12.029. eCollection 2016 Mar.

8.

Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy.

Brown WV, Foody JM, Zieve FJ, Tomassini JE, Shah A, Tershakovec AM.

J Clin Lipidol. 2016 Jan-Feb;10(1):116-23. doi: 10.1016/j.jacl.2015.10.002. Epub 2015 Oct 13.

PMID:
26892128
9.

Changing characteristics of statin-related cIMT trials from 1988 to 2006.

Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM.

Atherosclerosis. 2016 Mar;246:121-9. doi: 10.1016/j.atherosclerosis.2015.11.023. Epub 2015 Nov 25.

PMID:
26773471
11.

Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.

Krempf M, Simpson RJ Jr, Ramey DR, Brudi P, Giezek H, Tomassini JE, Lee R, Farnier M.

Lipids Health Dis. 2015 May 19;14:45. doi: 10.1186/s12944-015-0037-y.

12.

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.

Descamps O, Tomassini JE, Lin J, Polis AB, Shah A, Brudi P, Hanson ME, Tershakovec AM.

Atherosclerosis. 2015 Jun;240(2):482-9. doi: 10.1016/j.atherosclerosis.2015.03.004. Epub 2015 Mar 9.

PMID:
25913444
13.

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.

Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.

PMID:
25463129
14.

Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.

Bays HE, Chen E, Tomassini JE, McPeters G, Polis AB, Triscari J.

Fundam Clin Pharmacol. 2015 Apr;29(2):209-18. doi: 10.1111/fcp.12096. Epub 2015 Feb 27.

PMID:
25431239
15.

Combination therapy in dyslipidemia: where are we now?

Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tershakovec AM.

Atherosclerosis. 2014 Nov;237(1):319-35. doi: 10.1016/j.atherosclerosis.2014.09.026. Epub 2014 Sep 30. Review.

PMID:
25299967
16.

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR.

Vasc Health Risk Manag. 2014 Apr 25;10:237-46. doi: 10.2147/VHRM.S54886. eCollection 2014.

17.

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.

Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2014 Jan-Feb;8(1):107-16. doi: 10.1016/j.jacl.2013.09.009. Epub 2013 Oct 1.

PMID:
24528691
18.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

19.

Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.

Simpson RJ Jr, Tunceli K, Ramey DR, Neff DR, Kern DM, Hsieh HM, Wertz DA, Stephenson JJ, Marrett E, Tomassini JE, Jacobson TA.

J Clin Lipidol. 2013 Sep-Oct;7(5):399-407. doi: 10.1016/j.jacl.2013.06.002. Epub 2013 Jun 18.

PMID:
24079280
20.

Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.

Davidson MH, Voogt J, Luchoomun J, Decaris J, Killion S, Boban D, Glass A, Mohammad H, Lu Y, Villegas D, Neese R, Hellerstein M, Neff D, Musliner T, Tomassini JE, Turner S.

Atherosclerosis. 2013 Oct;230(2):322-9. doi: 10.1016/j.atherosclerosis.2013.08.006. Epub 2013 Aug 13.

PMID:
24075764
21.

Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.

Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW.

J Am Heart Assoc. 2013 Aug 7;2(4):e000037. doi: 10.1161/JAHA.113.000037.

22.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.

J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.

PMID:
23890516
23.

Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis.

Keane WF, Tomassini JE, Neff DR.

J Atheroscler Thromb. 2013;20(2):123-33. Epub 2012 Oct 25. Review.

24.

Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Thongtang N, Lin J, Schaefer EJ, Lowe RS, Tomassini JE, Shah AK, Tershakovec AM.

Atherosclerosis. 2012 Dec;225(2):388-96. doi: 10.1016/j.atherosclerosis.2012.09.001. Epub 2012 Sep 13.

25.

Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.

Toth PP, Ballantyne CM, Davidson MH, Tomassini JE, Ramey DR, Neff D, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2012 Mar-Apr;6(2):180-91. doi: 10.1016/j.jacl.2011.11.007. Epub 2011 Dec 7.

PMID:
22385552
26.

Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.

Guyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, Tershakovec AM.

Diabetes Care. 2012 Apr;35(4):857-60. doi: 10.2337/dc11-1369. Epub 2012 Feb 14.

27.

Intestinal sterol transporters and cholesterol absorption inhibition.

Davis HR Jr, Tershakovec AM, Tomassini JE, Musliner T.

Curr Opin Lipidol. 2011 Dec;22(6):467-78. doi: 10.1097/MOL.0b013e32834c7c28. Review.

PMID:
22101558
28.

Lipid abnormalities in patients with chronic kidney disease.

Keane WF, Tomassini JE, Neff DR.

Contrib Nephrol. 2011;171:135-42. doi: 10.1159/000327317. Epub 2011 May 23. Review.

PMID:
21625102
29.

Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).

Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2011 Jul 1;108(1):40-6. doi: 10.1016/j.amjcard.2011.03.003. Epub 2011 May 10.

PMID:
21565322
30.

Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients.

Tunceli K, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tomassini JE, Foody JM.

J Clin Lipidol. 2010 Nov-Dec;4(6):491-500. doi: 10.1016/j.jacl.2010.10.004. Epub 2010 Oct 13.

PMID:
21122696
31.

Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients.

Foody JM, Sajjan SG, Hu XH, Ramey DR, Neff DR, Tershakovec AM, Tomassini JE, Wentworth C, Tunceli K.

J Clin Lipidol. 2010 Mar-Apr;4(2):126-32. doi: 10.1016/j.jacl.2010.01.007. Epub 2010 Feb 6.

PMID:
21122640
32.

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.

Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM.

Diabetes Obes Metab. 2010 Nov;12(11):983-93. doi: 10.1111/j.1463-1326.2010.01289.x.

PMID:
20880345
33.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
34.

Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.

Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis AB, Tipping D, Tomassini JE, Tershakovec AM.

Diabetes Care. 2010 May;33(5):1021-4. doi: 10.2337/dc09-1762. Epub 2010 Feb 11.

36.

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).

Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, Polis AB, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2009 Jun 15;103(12):1694-702. doi: 10.1016/j.amjcard.2009.05.003.

PMID:
19539078
37.

Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.

Tomassini JE, Mazzone T, Goldberg RB, Guyton JR, Weinstock RS, Polis A, Jensen E, Tershakovec AM.

Diabetes Obes Metab. 2009 Sep;11(9):855-64. doi: 10.1111/j.1463-1326.2009.01061.x. Epub 2009 Jun 5.

PMID:
19508464
38.

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.

Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2008 Dec 1;102(11):1495-501. doi: 10.1016/j.amjcard.2008.09.076. Epub 2008 Oct 23.

PMID:
19026303
39.

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.

Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2008 Dec 1;102(11):1489-94. doi: 10.1016/j.amjcard.2008.09.075. Epub 2008 Oct 23.

PMID:
19026302
40.

Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery.

Itani KM, Jensen EH, Finn TS, Tomassini JE, Abramson MA.

Surg Infect (Larchmt). 2008 Apr;9(2):131-7. doi: 10.1089/sur.2007.034.

PMID:
18426345
41.

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.

J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.

42.

Ezetimibe: cholesterol lowering and beyond.

Bays HE, Neff D, Tomassini JE, Tershakovec AM.

Expert Rev Cardiovasc Ther. 2008 Apr;6(4):447-70. doi: 10.1586/14779072.6.4.447. Review.

PMID:
18402536
43.

Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.

Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, Lin J, Shah A, Tershakovec AM.

J Clin Lipidol. 2008 Feb;2(1):25-35. doi: 10.1016/j.jacl.2008.01.001. Epub 2008 Jan 11.

PMID:
21291712
44.

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.

Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E; Protocol 11 study Investigators.

Vaccine. 2008 Jan 30;26(5):686-96. doi: 10.1016/j.vaccine.2007.11.043. Epub 2007 Dec 5.

PMID:
18164106
45.

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.

Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA.

Vaccine. 2007 May 22;25(21):4324-33. Epub 2007 Mar 12.

PMID:
17445955
47.

Identification of diverse microbial metabolites as potent inhibitors of HIV-1 Tat transactivation.

Jayasuriya H, Zink DL, Polishook JD, Bills GF, Dombrowski AW, Genilloud O, Pelaez FF, Herranz L, Quamina D, Lingham RB, Danzeizen R, Graham PL, Tomassini JE, Singh SB.

Chem Biodivers. 2005 Jan;2(1):112-22.

PMID:
17191924
48.

Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.

Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM.

Mayo Clin Proc. 2006 Dec;81(12):1579-88. Erratum in: Mayo Clin Proc. 2007 Mar;82(3):387.

PMID:
17165637
49.

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.

Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.

Curr Med Res Opin. 2006 Oct;22(10):2041-53.

PMID:
17022864
50.

Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.

Tomassini JE, Getty K, Stahlhut MW, Shim S, Bhat B, Eldrup AB, Prakash TP, Carroll SS, Flores O, MacCoss M, McMasters DR, Migliaccio G, Olsen DB.

Antimicrob Agents Chemother. 2005 May;49(5):2050-8.

Supplemental Content

Loading ...
Support Center